BioSpace News Archive

ARASENS trial with darolutamide in combination with docetaxel and androgen deprivation therapy meets primary endpoint of significantly increasing overall survival in patients with metastatic hormone-sensitive prostate cancer

The Phase III ARASENS trial investigating the use of the oral androgen receptor inhibitor NUBEQA® in metastatic hormone-sensitive prostate cancer has met its primary endpoint.

United Therapeutics (Nasdaq: UTHR), a public benefit corporation with a purpose to provide a brighter future for patients, today announced that the company has been named on Newsweek’s list of America’s Most Responsible Companies 2022.

Bausch Health Companies Inc. today introduced a collection of digital and social activations aimed at helping adult patients with opioid-induced constipation (OIC), irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC).

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted six newly-hired employees inducement options to purchase an aggregate of 18,000 shares of KalVista common stock on December 1, 2021 as inducements material to each employee entering into employment with KalVista.

Vivos Therapeutics, Inc. today announced that Vivos’ Chairman and Chief Executive Officer, Kirk Huntsman, and Vivos’ Chief Financial Officer, Brad Amman, will be presenting at the online Benzinga Global Small Cap Conference at 1:55 pm EST on Thursday, December 9, 2021.

Junshi Biosciences announced today that the company’s product toripalimab continues to be included in Category B in the National Drug List for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance (2021 Edition).

Dr. Weiner Brings Chemomab Extensive Biotechnology and Pharmaceutical Industry R&D and Strategic Experience, Including Overseeing the Design and Management of Clinical Trials for Rare and Challenging Therapeutic Indications.

The COSMOS study met its primary endpoint, with a significantly higher proportion of TREMFYA-treated patients (44.4 percent) versus placebo-treated patients (19.8 percent) achieving ACR20 response at week 24.

Cardiff Oncology, Inc. today announced that on December 2, 2021, non-qualified stock option awards to purchase an aggregate of 200,112 shares of its common stock were granted to two new employees.